Lipid-based nanoparticles are pivotal in modern medicine, improving drug delivery and mRNA therapies through innovative ...
Young people’s risk of developing myocarditis is higher and longer lasting after covid-19 infection than after vaccination against it, the largest study of its kind suggests.1 The research—based on ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...
Opinion
A medical breakthrough saved millions of lives during COVID. Why are we turning our backs on it now?
The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA vaccines against potentially ...
Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 ...
Pfizer has axed 11 programs, including two pipeline assets from its $43 billion Seagen acquisition, work on a ...
Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...
The official opening will be headlined by Dr Nomalungelo Gina, Deputy Minister of Science, Technology and Innovation, who ...
Zacks Investment Research on MSN
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate ...
The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...
Backed by fresh European financing, BioNTech’s Kigali facility is emerging as the cornerstone of Africa’s mRNA vaccine ...
By stimulating cancer cells to produce a molecule that activates a signaling pathway in nearby immune cells, MIT researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback